** Shares of New Zealand's Fisher & Paykel Healthcare Corp FPH.NZ up 1% at NZ$36.53
** The medical equipment maker to report FY25 results on Wednesday
** Morgan Stanley expects FY26 NPAT forecast of NZ$422 million ($253.16 million) vs Visible Alpha estimate of NZ$426 million
** Brokerage says FY26 forecasts imply limited gross margin expansion due to expected U.S. tariff impacts on products manufactured in New Zealand
** MS to focus on impacts from most recent U.S. flu season and trends for new applications growth in co's hospitals segment
** Brokerage also looking for co's updates on newer mask launches and commentary on potential impact of GLP-1s on the obstructive sleep apnea (OSA) market
** Stock rated "equal-weight" with a price target of NZ$36.7
** Fisher & Paykel down 5.1% YTD, including current session's moves
($1 = 1.6669 New Zealand dollars)
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。